CompletedNot Applicable

Impact of an Increased Restrictive Factor of One Anastomosis Gastric Bypass on Metabolic Outcomes Type 2 Diabetes.

Kazakhstan300 participantsStarted 2020-01-13

Plain-language summary

The purpose of the study is to evaluate the effect of an increased restrictive factor of one gastric anastomosis (OAGB) using a "FundoRing" fundoplication on metabolic outcomes in type 2 diabetes mellitus. The randomized controlled trial compared two interventional procedures: one group - using the original fundoplication procedure to enhance the restrictive effect and another group without fundoplication in the standard version of the OAGB.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * BMI 25-55 kg/m2 * Patients with Diabetes Mellitus, Type 2 Exclusion Criteria: * BMI \<25 and \>55 kg/m2 * Patients without Diabetes Mellitus, Type 2 * History of surgery on the stomach * Less than 18 or more than 60 years of age * Psychiatric illness * Patients unwilling or unable to provide informed consent

What they're measuring

Metabolic improvements of type 2 diabetes

Timeframe: Baseline, at 12, 24, 36 months after surgery

Trial details

NCT IDNCT06176443

SponsorThe Society of Bariatric and Metabolic Surgeons of Kazakhstan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-13

View on ClinicalTrials.gov More Obesity, Morbid trials